IGM BIOSCIENCES INC (IGMS) 24 -1.4 (-5.51%)
24 -1.4 (-5.51%)
US4495851085 - Common Stock - After market: 24 0 (0%)
IGM BIOSCIENCES INC24
NASDAQ:IGMS (2/3/2023, 7:00:03 PM)-1.4 (-5.51%)
| GICS Sector | Health Care | ||
| GICS Industry | Biotechnology | ||
| Valuation | Growth | ||
| Profitability | Health | ||
| Dividend | |||
| Earnings (Last) | 11-03 2022-11-03/bmo | Earnings (Next) | 03-27 2023-03-27/amc |
| Ins Owners | 0.76% | Inst Owners | 41.29% |
| Market Cap | 1.03B | Shares | 42.83M |
| PE | N/A | Fwd PE | N/A |
| Dividend Yield | N/A | Analysts | 84.71 |
| IPO | 09-18 2019-09-18 | ||
Stock Screener Links
Nasdaq Stock Screener
Find more stocks on Nasdaq
USA Stock Screener
Find more stocks on the USA
GICS Sector Stock Screener
Find competitors from the same sector on the USA
GICS Industry Stock Screener
Find competitors from the same industry on the USA
Technical Stock Screener
Find stocks with similar TA and Setup ratings on the USA
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Technical Competitors Stock Screener
Find the competitors with the best technical ratings on the USA
Best Technical Setups Competitors Stock Screener
Find the competitors with the best technical and setup ratings on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA
Best Analyst Rating Competitors Stock Screener
Find the competitors with the best analyst ratings on the USA
Company Profile
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 242 full-time employees. The company went IPO on 2019-09-18. The firm has created an IgM antibody technology platform for developing T cell engagers, receptor cross-linking agonists, targeted cytokines and target neutralizers. Its product candidates in clinical testing include IGM-2323 and IGM-8444. IGM-2323 is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in a Phase II clinical trial for the treatment of relapsed/refractory B cell non-Hodgkins lymphoma (NHL) patients. IGM-8444 is an IgM antibody targeting Death Receptor 5 (DR5) proteins for the treatment of patients with solid and hematologic malignancies, is in a Phase I clinical trial for the treatment of solid cancers. Its oncology pipeline also includes IGM-7354, IGM-2644 and IGM-2537.
Company Info
IGM BIOSCIENCES INC
325 E Middlefield Rd
Mountain View CALIFORNIA 94043
P: 16509657873.0
CEO: Fred Schwarzer
Employees: 242
Website: https://igmbio.com/
IGMS News
3 days ago - IGM Biosciences, Inc.IGM Biosciences to Present at the Guggenheim 2023 Oncology ConferenceMOUNTAIN VIEW, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating...
19 days ago - IGM Biosciences, Inc.IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors– Targeted IL-15/IL-15R IgM antibody to be evaluated for safety and pharmacodynamic effects –
21 days ago - MedivirMedivir to present at the Redeye Fight Cancer Day/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...
25 days ago - Market News VideoIGM Biosciences (IGMS) Shares Cross Above 200 DMAa month ago - IGM Biosciences, Inc.IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical DevelopmentIGMS Twits
Here you can normally see the latest stock twits on IGMS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
